Pharmaceuticals Global On demand · 24-48h

Global Luteinizing Hormone Receptor Market Strategic Research Report

Global Luteinizing Hormone Receptor Market Strategic Researc…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Luteinizing Hormone Receptor Market
$8.022025
5.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Luteinizing Hormone Receptor Antibodies, Recombinant Luteinizing Hormone Receptor Proteins and Peptides, Luteinizing Hormone Receptor Assay Kits, Luteinizing Hormone Receptor Gene and Cell Products, Others

By Application: Medical Care, Experiment, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Merck KGaA, Danaher, Bio-Techne, GenScript, Proteintech, OriGene Technologies, Santa Cruz Biotechnology, MyBioSource, Abbexa, Abmgood, Creative Biolabs, Creative Diagnostics, RayBiotech, Boster Bio, ABclonal, Elabscience, FineTest, Bioss Antibodies, Signalway Antibody, Affinity Biosciences, XpressBio, Assay Genie, Biorbyt, Abnova, GeneTex, Biotium, NSJ Bioreagents, Neobiotechnologies, ELK Biotechnology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 170 pages
Market size 2025
$8.02
Million USD
Forecast CAGR
5.8%
2025-2032
Forecast 2032
$11.9
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Luteinizing Hormone Receptor market size is predicted to grow from US$ 8.02 million in 2025 to US$ 11.94 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.

Luteinizing Hormone Receptor refers to a group of research-use biological reagents and model products targeting the Luteinizing Hormone Receptor, typically including antibodies, recombinant receptor fragments, synthetic peptides, assay kits, expression vectors, and stable cell models. Product appearance depends on format: antibodies are usually clear or slightly opalescent buffered liquids; recombinant proteins and peptides are commonly supplied as lyophilized powder or reconstituted solutions; assay kits consist of pre-coated plates, standards, enzyme-linked antibodies, substrates, and wash buffers; vector and cell products are delivered as plasmid solutions, viral vectors, or cryopreserved cells. The biological target is a membrane-localized seven-transmembrane receptor with a large glycosylated extracellular ligand-binding region, transmembrane domains, and intracellular signaling regions. It binds luteinizing hormone and chorionic gonadotropin, activates adenylate cyclase, cyclic AMP, and protein kinase signaling pathways, and thereby regulates steroidogenesis, ovulation, corpus luteum function, and Leydig cell activity. Key production requirements include antigen design, membrane protein expression, purification and refolding, antibody specificity validation, batch-to-batch consistency, low-endotoxin control, and application data verification. It is mainly used in reproductive endocrinology, assisted reproduction mechanism studies, tumor receptor expression research, drug screening, and animal model development.

Reproductive health, delayed childbearing, infertility mechanism studies, and assisted reproduction research form the main growth base for this market. Although Luteinizing Hormone Receptor products represent a small market, they sit at the intersection of reproductive endocrinology, ovarian function, testicular function, steroidogenesis, and receptor signaling. Future growth is expected to come mainly from validated antibodies, high-sensitivity assay kits, recombinant receptor fragments, stable expression cell models, and gene vector products, especially integrated product combinations that directly support mechanism studies, pharmacodynamic screening, and animal model validation.

The key restraints are technical complexity and fragmented demand. Luteinizing Hormone Receptor is a transmembrane receptor, so native full-length expression and purification are technically demanding. Antibody specificity, tissue staining background, batch-to-batch consistency, and cross-species reactivity can all affect experimental reliability. Most products are restricted to research use only and cannot be counted directly as clinical diagnostic products. At the same time, the antibody and assay kit market is highly homogeneous; some brands rely on outsourced or private-label supply, and insufficient validation data or price competition may compress the margins of smaller suppliers.

Downstream demand is moving from single-item reagent purchasing toward experimental solution purchasing. Universities, hospital research platforms, and pharmaceutical companies increasingly value the compatibility among antibodies, positive controls, recombinant proteins, vectors, cell models, and detection methods. Reproductive medicine remains the core demand area, while oncology, endocrine disease research, animal breeding, and drug discovery are expected to provide additional incremental demand. Purchasing decisions will increasingly depend on literature citations, validation images, lot stability, delivery speed, and technical support rather than catalog price alone.

This report presents a comprehensive overview of the global Luteinizing Hormone Receptor market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Luteinizing Hormone Receptor Antibodies
  • Recombinant Luteinizing Hormone Receptor Proteins and Peptides
  • Luteinizing Hormone Receptor Assay Kits
  • Luteinizing Hormone Receptor Gene and Cell Products
  • Others

Segment by Pack Size

  • 10 mg
  • 20 mg
  • 50 mg
  • Others

Segment by Application

  • Medical Care
  • Experiment
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Luteinizing Hormone Receptor market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Medical Care, Experiment, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Luteinizing Hormone Receptor Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$8.02
2025
Forecast
$11.9
2032
CAGR
5.8%
2025–2032
Regionen
5
global
Key companies
Thermo Fisher ScientificMerck KGaADanaherBio-TechneGenScriptProteintechOriGene TechnologiesSanta Cruz Biotechnology
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Luteinizing Hormone Receptor AntibodiesRecombinant Luteinizing Hormone Receptor Proteins and PeptidesLuteinizing Hormone Receptor Assay KitsLuteinizing Hormone Receptor Gene and Cell ProductsOthers
By Application
Medical CareExperimentOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Luteinizing Hormone Receptor Antibodies
  • 3.1.3 Recombinant Luteinizing Hormone Receptor Proteins and Peptides
  • 3.1.4 Luteinizing Hormone Receptor Assay Kits
  • 3.1.5 Luteinizing Hormone Receptor Gene and Cell Products
  • 3.1.6 Others
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Medical Care
  • 4.1.3 Experiment
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Merck KGaA
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Danaher
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bio-Techne
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 GenScript
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Proteintech
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 OriGene Technologies
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Santa Cruz Biotechnology
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 MyBioSource
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Abbexa
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Abmgood
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Creative Biolabs
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Creative Diagnostics
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 RayBiotech
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Boster Bio
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 ABclonal
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Elabscience
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 FineTest
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Bioss Antibodies
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Signalway Antibody
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Affinity Biosciences
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 XpressBio
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Assay Genie
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Biorbyt
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Abnova
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 GeneTex
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Biotium
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 NSJ Bioreagents
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 Neobiotechnologies
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 ELK Biotechnology
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Luteinizing Hormone Receptor market?
The global Luteinizing Hormone Receptor market is estimated at US$ 8.02 million in 2025 (base year) and is projected to reach US$ 11.94 million by 2032.
How fast is the Luteinizing Hormone Receptor market expected to grow?
The market is expected to grow at a CAGR of 5.8% from 2026 to 2032, expanding from US$ 8.02 million in 2025 to US$ 11.94 million in 2032, roughly 1.5 times its base-year value.
What does the Luteinizing Hormone Receptor market cover?
Luteinizing Hormone Receptor refers to a group of research-use biological reagents and model products targeting the Luteinizing Hormone Receptor, typically including antibodies, recombinant receptor fragments, synthetic peptides, assay kits, expression vectors, and stable cell models. The biological target is a membrane-localized seven-transmembrane receptor with a large glycosylated extracellular ligand-binding region, transmembrane domains, and intracellular signaling regions.
What are the main segments of the Luteinizing Hormone Receptor market by type?
By type, the market is segmented into Luteinizing Hormone Receptor Antibodies, Recombinant Luteinizing Hormone Receptor Proteins and Peptides, Luteinizing Hormone Receptor Assay Kits, Luteinizing Hormone Receptor Gene and Cell Products and Others.
Which applications drive demand in the Luteinizing Hormone Receptor market?
Key applications covered include Medical Care, Experiment and Others.
Who are the key players in the Luteinizing Hormone Receptor market?
Key players profiled include Thermo Fisher Scientific, Merck KGaA, Danaher, Bio-Techne, GenScript, Proteintech, OriGene Technologies and Santa Cruz Biotechnology, among 30 companies covered in total.
Which regions and countries are covered for Luteinizing Hormone Receptor?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What challenges does the Luteinizing Hormone Receptor market face?
The key restraints are technical complexity and fragmented demand.
Who should buy the Luteinizing Hormone Receptor market report?
The report is intended for manufacturers and solution providers, distributors and end users in Medical Care, Experiment and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Luteinizing Hormone Receptor market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.